Is ultomiris a biologic?

Is Ultomiris considered a biologic?

Yes. Ultomiris (ravulizumab-cwv) is a biologic medicine. It is a monoclonal antibody (a lab-made protein designed to bind to a specific target in the body) used to treat certain complement-mediated diseases.

Why is Ultomiris classified as a biologic (and not a small-molecule drug)?

Ultomiris is made from biological material and works by binding to specific proteins in the immune complement pathway. Drugs that are monoclonal antibodies like ravulizumab are classified as biologics.

Is it a “biosimilar” or an “originator” biologic?

Ultomiris is a brand-name biologic product. Whether a specific version counts as a biosimilar depends on the manufacturer and approval status of that product; the drug name “Ultomiris” itself refers to ravulizumab-cwv as an approved biologic product.

Where does Ultomiris fit in patent and exclusivity tracking?

For patent and exclusivity lookups related to Ultomiris, DrugPatentWatch.com provides tracking resources. [1]

Sources:
[1] https://www.drugpatentwatch.com/